ClinPGx Blog (Page 41)

Sign in Subscribe

More issues

Big Data in Biomedicine

PharmGKB Developers and Curators attended the Big Data in Biomedicine conference this week, organized by Stanford University and the University of Oxford. The talks and panels raised a plethora of issues surrounding storing, sharing, analyzing, validating, visualizing and utilizing Big Data for improving healthcare and to drive change. Among the

New name for IL28B gene = IFNL3

PharmGKB has updated our gene names that comply with The Human Genome Nomenclature Committee (HGNC) approved symbol, approved name, and synonyms. One particular name change we would like to highlight with this update: The HGNC-approved gene symbol for IL28B is now IFNL3 (interferon lambda 3) - a gene with variants

Curators' Favorite Papers

The current Curators' Favorite Papers' highlights the higher frequency of genetic variants conferring increased risk for adverse drug reactions (ADRs) for many commonly used drugs in persons of African descent. Differences in drug response, cure rates and survival outcomes between different ethnic populations exist. To assess this, Aminkeng

Updated UGT1A1 VIP Summary

We have updated the UGT1A1 VIP summary to provide more in-depth information on this important pharmacogene. UGT1A1 is a member of the uridine diphosphate glucuronosyltransferase (UGT) enzyme family, and is responsible for the glucuronidation of target substrates. The transfer of glucuronic acid renders xenobiotics and other endogenous compounds water soluble,

The PGRN Translational Pharmacogenetics Program (TPP) publishes paper on overcoming challenges of real-world implementation

The Translational Pharmacogenetics Program (TPP) is a Pharmacogenomics Research Network (PGRN)-led initiative with the goal to identify barriers and develop real-world solutions to implement evidence-based pharmacogenetic tests in diverse health care settings. The participating sites include 6 implementation institutions (Universityof Maryland, University of Florida, St. Jude Children's

Implementing pharmacogenetics: more than one gene at a time

It has been well recognized that drug response is complex and determined by not only one gene, but rather by the interplay of multiple gene products. However, studies of combined impact of more than one gene are scarce, limiting the potential for making strong dosing recommendations based on multiple genes.

Clinical notes used for pharmacovigilance

A team at Stanford University have computationally extracted information from free-text clinical notes in medical records, in order to identify drug-induced adverse events and adverse reactions from drug-drug interactions. Information from the notes was deidentified and transformed into a patient-feature matrix using a medical ontology hierarchy system. They demonstrate that

Venlafaxine Pathway

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed for the treatment of depression disorders. The molecular targets of venlafaxine are the serotonin and norepinephrine transporters, resulting in inhibition of serotonin and noradrenaline reuptake from the synaptic cleft. A new pathway is posted on PharmGKB summarizing the metabolism of venlafaxine. Demethylation

Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics

We updated the Mycophenolic acid Pathway in collaboration with Kinjal Sanghavi and Dr. Vishal Lamba from the University of Minnesota.Mycophenolic Acid (MPA) is an immunosuppressive agent and is indicated as prophylactic agent in patients receiving allogeneic renal, cardiac or hepatic transplants. This PharmGKB pathway describes the steps and metabolites

GWAS in PGx: Pharmacogenomics Special Issue

This month's Future Medicine Pharmacogenomics Journal focuses on genome-wide association studies (GWAS) in PGx. Articles include highlights from the latest PGx GWAS, and topics covering data analysis techniques, rare variants, and direct-to-consumer PGx testing. Pharmacogenomics, March 2013, Volume 14, Number 4 Special Focus Issue: Genome-wide association studies in